Janssen/MeiraGTx showcase nine-month data for sight loss gene therapy
Gene therapy demonstrated improvement in retinal sensitivity
Read More
Tag: MeiraGTx
Janssen/MeiraGTx sight loss gene therapy hits targets
Interim six-month data of RPGR gene therapy shows significant vision improvement in patients with X-linked retinitis pigmentosa
Read More
Janssen and MeiraGTx team up to fight inherited retinal diseases
MeiraGTx has announced a strategic collaboration with Johnson & Johnson’s Janssen to develop and commercialise gene therapy treatments for inherited retinal diseases (IRDs).
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
